Royalty Report: Drugs, Cancer, Therapeutic – Collection: 192689

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Specialty

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 192689

License Grant
The Company granted Licensee an exclusive, worldwide license to develop and commercialize its small molecule arginase inhibitors for hematology and oncology indications.
License Property
The company has identified CB-1158 and a portfolio of other small molecule arginase inhibitors that show high potency and oral bioavailability.

CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells.

Field of Use
This agreement relating to the drug industry relating tumor metabolism and tumor immunology targets for the treatment of cancer.

IPSCIO Record ID: 241600

License Grant
The Licensor grants to the Cayman Islands Licensee an exclusive royalty-bearing, non-sublicensable, non-transferable license under the Licensor Technology and interest in the Joint Combination Therapy Technology to Commercialize Licensed Products in the Field in the Territory.
License Property
Technology relates to he oral inhibitor enzyme is Ivosidenib for the treatment of hematologic and solid tumor indications.  Ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme.

Ivosidenib is an investigational first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation. IDH1 is a metabolic enzyme that is mutated in a wide range of cancers, including acute myeloid leukemia, cholangiocarcinoma and glioma. Ivosidenib is currently under U.S. FDA priority review for IDH1m R/R AML patients with a PDUFA action date of August 21, 2018.

Field of Use
Licensee has expertise in the development of biopharmaceutical products and will be responsible for conducting the development and commercialization activities for ivosidenib in hematologic and solid tumor indications.

IPSCIO Record ID: 228840

License Grant
The company entered into a license agreement with the nonprofit Licensor covering a new group of molecules recently discovered in connection with research the company have been sponsoring called WP1732, a part of the WP1066 Portfolio.
License Property
The focus is on the development of oncology drug candidates with the following core drug technologies a uniquely designed anthracycline (Annamycin), a portfolio of STAT3 inhibitors (WP1066 Portfolio) and a collection of inhibitors of glycolysis (WP1122 Portfolio).

WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.

WP1732, a new molecule in the WP1066 portfolio.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 246211

License Grant
The Licensor hereby grants to the Licensee an exclusive, worldwide, royalty-bearing license under Licensors rights in the Licensed Technology to make, develop, use, sell, offer for sale and import Licensed Products in the Field. Such license shall include the right to grant sublicenses. The IP is a proprietary biological molecule that inhibits soluble tumor necrosis factor.
License Property
The Licensor has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor.

INB03 is a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells.

Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.

Field of Use
Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 262535

License Grant
Hong Kong Licensor, a related-party of the Company,( Licensee CEO and one director have controlling interest in the Parent of the Licensor), granted Licensee an exclusive, sublicensable right and license to develop and commercialize products containing pegylated and cobalt-replaced arginase for the treatment of cancer in humans, apart from ophthalmic uses and use as eye drops, worldwide.  

The Licensor is an entity affiliated with a related-party of the Company.  The Licensee's chief executive officer and chairman, and one of the  directors, collectively have a controlling interest in, and serve on the board of directors of the affiliated entity.

License Property
The companies are dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Pegylated genetically engineered human arginase, targets cancer growth and survival by interrupting the supply of an essential amino acid, arginine, to a proportion of cancers with disrupted urea cycle. Our proprietary arginase biologic product is designed to deplete arginine from tumors with disrupted urea cycle, while healthy cells, capable of producing their own arginineare largely unaffected.
Field of Use
“Field” means the treatment of cancer in humans, apart from ophthalmic uses and use as eye-drops.

IPSCIO Record ID: 255299

License Grant
Licensor have entered into an exclusive collaboration and license agreement with Chinese Licensee involving three immuno-oncology (I-O) programs from Licensor's pipeline of product candidates margetuximab, MGD013 and an undisclosed multi-specific Trident molecule in preclinical development.
License Property
Margetuximab is an immune-optimized anti-HER2 monoclonal antibody currently being evaluated in Phase 3 metastatic breast cancer with anticipated topline. Margetuximab is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2, oncoprotein. HER2 is expressed by tumor cells in breast, gastric, and other solid tumor cancers, making it a key marker for biologic therapy.

MGD013 is a first-in-class bispecific DART molecule designed to provide coordinate blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for the potential treatment of a range of solid tumors and hematological malignancies.

Field of Use
Licensee is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer.

IPSCIO Record ID: 369281

License Grant
Licensor hereby grants to Licensee and its Affiliates, and Licensee and its Affiliates hereby accept, an exclusive (even as to Licensor), royalty-bearing right and license (with the right to grant sublicenses in accordance with the provisions of Agreement) under the Licensor Technology to research, Develop, have Developed, Manufacture, have Manufactured, use, import, Commercialize and have Commercialized the Compound and Licensed Products in and for the Field and Territory.
License Property
Patent Application titles Novel Heterocyclic Compounds as BRD4 Inhibitors.

The BET inhibitor program is from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.

There is emerging preclinical data showing BET inhibitors may enhance the activity of immuno-oncology agents, such as anti-PD-1/PD-L1 antibodies, providing multiple opportunities for us to combine this novel mechanism within our portfolio.  Epigenetic targeted agents, especially BET inhibitors, have been an area of great interest of ours for some time and are particularly attractive to us because of their effects on c-Myc driven tumors, like aggressive GCB-subtype DLBCL, an area we have seen early activity with TGR-1202 and our proprietary combination referred to as TG-1303.

Field of Use
The sub-license agreement is to develop and commercialize Jubilant’s novel BET inhibitor program in the field of hematological malignancies.

Field means all prophylactic, palliative, therapeutic or diangnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemia’s, Lymphoma’s, Multipe Myeloma and Waldenstrom’s Macroglobulinemia.

IPSCIO Record ID: 306778

License Grant
Licensor (i) assigned to Licensee its patents/patent applications covering XP-102, known as BI 882370, a 2nd-generation pan-RAF inhibitor; and (ii) granted Licensee a worldwide, exclusive, royalty-bearing, and non-transferable license to all know-how controlled by Licensor or affiliates necessary for, or specifically related to, the discovery, development, manufacture, commercialization, or use of XP-102 and any family compound.
License Property
XP-102 is a second generation potent and selective pan-RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase. It is an oral small molecule drug candidate that is being developed for the potential treatment of colorectal cancer, melanoma, non-small cell lung cancer, hairy cell leukemia, and potentially other cancer types.

Licensor focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.

Field of Use
XP-102 for all human and non-human diagnostic, prophylactic, and therapeutic uses, including therapeutic uses targeting hematological and solid tumors.  It is being developed for the potential treatment of colorectal cancer, melanoma, non-small cell lung cancer, hairy cell leukemia, and potentially other cancer types.

Licensee is a biopharmaceutical company that discovers and develops innovative small molecule drug candidates for the treatment of cancer in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.